Bicycle Therapeutics plc, a clinical-stage biopharmaceutical firm, is working on developing a new class of medications to treat ailments that are currently underserved by existing treatments. The firm's pipeline consists of various products that are undergoing clinical trials across multiple indications. Its lead product, BT1718, is a bicycle toxin conjugate (BTC) that is undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Another BTC, BT5528, is currently in a Phase I/II clinical trial targeting Ephrin type-A receptor 2, while BT8009 is in Phase I/II clinical trial targeting Nectin-4. Additionally, the company is developing THR-149, a plasma kallikrein inhibitor to treat diabetic macular edema, and BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing. Further, the company collaborates with other biopharmaceutical companies and organizations to advance programs in therapeutic areas such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. Bicycle Therapeutics plc has several partnerships in place, including a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK, research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc. Furthermore, the firm has a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was established in 2009 and is headquartered in Cambridge, the United Kingdom.
Bicycle Therapeutics plc's ticker is BCYC
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Cambridgeshire
There are 51-200 employees working at Bicycle Therapeutics plc
It is https://www.bicycletherapeutics.com/
Bicycle Therapeutics plc is in the Healthcare sector
Bicycle Therapeutics plc is in the Biotechnology industry
The following five companies are Bicycle Therapeutics plc's industry peers: